Business
REGENXBIO Reports First Quarter 2020 Financial Results and Operational Highlights
- Positive long-term and interim data update from RGX-314 Phase I/IIa trial for wet AMD recently announced - RGX-314 clinical trials for treatment of wet AMD
About this update from Regenxbio Inc.
[{"type":"text","content":"- Positive long-term and interim data update from RGX-314 Phase I/IIa trial for wet AMD recently announced\n - RGX-314 clinical trials for treatment of wet AMD and diabetic retinopathy to advance in 2020 using subretinal and suprachoroidal delivery approaches\n - Additional interim data from RGX-121 Phase I/II trial for MPS II expected in 2020\n - Revenue includes $10 million in royalties from the Q1 2020 sales of Novartis' Zolgensma®; Zolgensma has recorded total net sales of over $530 million since launch\n - $357 million in cash, cash equivalents and marketable securities as of March 31, 2020\n - Conference call Thursday, May 7th, at 4:30 p.m. ET\n\n\nROCKVILLE, Md., May 7, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced financial results for the quarter ended March 31, 2020, and recent operational highlights.\n\"Our overall focus at REGENXBIO during the COVID-19 pandemic is on the health and safety of our people and our communities, as well as the important work that we need to continue in order to help patients,\" said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. \"We recently reported additional positive data from our RGX-314 Phase I/IIa wet AMD trial which demonstrated long-term, sustained clinical outcomes in patients after a one-time administration of RGX-314 gene therapy. We look forward to initiating a pivotal program for the subretinal delivery of RGX-314 for wet AMD as well as additional studies using the suprachoroidal delivery approach in both wet AMD and diabetic retinopathy in 2020. We also anticipate providing updates throughout 2020 from our other programs, including the Phase I/II trials of RGX-121 for the treatment of MPS II and RGX-501 for the treatment of HoFH.\"\nMr. Mills added: \"We continue to track the positive progress of Novartis' Zolgensma which uses the NAV AAV9 vector for the treatment of pediatric patients with spinal muscular atrophy (SMA). We are encouraged by the recent regulatory updates from Japan and Europe, and we look forward to continued sales growth for Zolgensma. After more than a decade of steadfast effort and focus, we remain dedicated and committed to improving lives thr...